Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bue Ross Agner

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Danish Medical Journal|September 7, 2012
Vitamin D deficiency is unrelated to type of atrial fibrillation and its complicationsFaiza Qayyum, Nadia Lander Landex, Bue Ross Agner, et al.
Diabetes, Obesity & Metabolism|August 20, 2019
Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trialHirotaka Watada, Shizuka Kaneko, Mitsuhisa Komatsu, et al.
Diabetes, Obesity & Metabolism|August 14, 2019
Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trialKohei Kaku, Eiichi Araki, Yukio Tanizawa, et al.
Plos One|June 8, 2019
Recurrent event survival analysis predicts future risk of hospitalization in patients with paroxysmal and persistent atrial fibrillationJakob Schroder, Olivier Bouaziz, Bue Ross Agner, et al.
Ugeskrift for Laeger|March 6, 2024
Bue Ross Agner, Caroline Hasselbalch Riley, Søren Lykke Petersen, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Danish Medical Journal|September 7, 2012
Vitamin D deficiency is unrelated to type of atrial fibrillation and its complicationsFaiza Qayyum, Nadia Lander Landex, Bue Ross Agner, et al.
Diabetes, Obesity & Metabolism|August 20, 2019
Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trialHirotaka Watada, Shizuka Kaneko, Mitsuhisa Komatsu, et al.
Diabetes, Obesity & Metabolism|August 14, 2019
Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trialKohei Kaku, Eiichi Araki, Yukio Tanizawa, et al.
Plos One|June 8, 2019
Recurrent event survival analysis predicts future risk of hospitalization in patients with paroxysmal and persistent atrial fibrillationJakob Schroder, Olivier Bouaziz, Bue Ross Agner, et al.
Ugeskrift for Laeger|March 6, 2024
Bue Ross Agner, Caroline Hasselbalch Riley, Søren Lykke Petersen, et al.
Pageof 1